Sarepta to seek speedy approval of third DMD drug

Sarepta Therapeutics plans to soon file for a speedy U.S. approval of an experimental treatment for Duchenne muscular dystrophy, reporting Thursday interim results from a late-stage trial that the company says could support an application for the drug, called casimersen.